Mitchell D. Schnall was re-elected co-chair of the ECOG-ACRIN Cancer Research Group by the Principal Investigator Committee.
Helen M. Piwnica-Worms and Fabrice André will be honored for their contributions to breast cancer research by the San Antonio Breast Cancer Symposium and the American Association for Cancer Research, an SABCS cosponsor, at the 2021 SABCS Dec. 7-10.
The Goldstein familyRuth “Rikki” Kutcher Goldstein made a $2 million gift to support cancer research at Indiana University School of Medicine.
An Indiana University research team led by Wade Clapp received renewal for an $11.4 million SPORE grant first awarded by NCI in 2015, supporting research into identifying new treatments for tumors that develop in neurofibromatosis type 1 (NF1), the most common inherited syndrome causing a predisposition to cancer.
GeoVax Labs Inc. and City of Hope entered into a license agreement granting GeoVax exclusive rights to further develop and commercialize COH04S1, a multi-antigenic SARS-CoV-2 investigational vaccine developed at City of Hope for immunocompromised patients.
NEXT Oncology entered into an agreement with the Quirónsalud Group to open two new phase I clinical trial centers in Spain.
The American Lung Association’s 4th annual “State of Lung Cancer” report showed that the lung cancer five-year survival rate increased 14.5% nationally to 23.7% yet remains significantly lower among communities of color.
According to the DREAMseq phase III clinical trial, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) (N/I), followed by the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) (D/T) if there was disease progression, led to a significant improvement in estimated 2-year overall survival from the start of treatment (72%) when compared to the opposite treatment sequence (52%).
According to a study led by University of Michigan researchers, fewer than one-third of hospitals had immediate availability of all-trans retinoic acid (ATRA), which is initiated early in the treatment of acute promyelocytic leukemia to prevent major bleeding, clotting, and potential death.
In findings led by researchers at Yale Cancer Center and collaborating institutions, the monoclonal antibody drug sotigalimab, combined with Bristol Myers Squibb’s immunotherapy drug Opdivo (nivolumab), resulted in tumor shrinkage in patients with advanced melanoma whose tumors had progressed on prior immunotherapy.
